TORONTO, Sept. 11, 2020 /CNW/ - Khiron Life Sciences
Corp. ("Khiron" or the "Company") (TSXV: KHRN), (OTCQX: KHRNF),
(Frankfurt: A2JMZC), a vertically
integrated cannabis leader with core operations in Latin America and Europe, announces the adoption of the
Company's amended and restated stock option plan and the
Company's amended and restated restricted share unit plan
(together, the "Share Compensation Plans"). The Share
Compensation Plans were approved by shareholders at the annual
general and special meeting of shareholders held on September 10, 2020 (the "AGM") and were
previously approved by the Company's board of directors and by the
TSX Venture Exchange ("TSXV"), subject to shareholder approval at
the AGM.
The board of directors may grant options and restricted share
units ("RSUs") under the Share Compensation Plans to attract,
motivate and retain directors, officers, employees and consultants,
and to align the interests of plan participants with those of the
Company's shareholders. The fixed number of shares issuable under
the Share Compensation Plans and any other securities compensation
arrangement (including the Company's previous stock option and RSU
plans) is 13,398,580, being 20% of the shares issued as at
August 4, 2020, less the number of
options and RSUs issued as at that date.
Following the approval by shareholders of the Share Compensation
Plans, on September 10, 2020, the
board of directors approved a grant of 1,210,000 RSUs to certain
directors and officers of the Company under the amended and
restated RSU plan, as set forth below. The RSUs will vest in
thirds on each of the first, second and third anniversaries of the
grant date.
Name
|
Title/Position
|
Number of
Shares
|
Chris
Naprawa
|
Chairman
|
400,000
|
Deborah
Rosati
|
Director
|
400,000
|
Alvaro
Yanez
|
Director
|
200,000
|
Rayet Harb
Gasi
|
Vice President,
Khiron Health
|
110,000
|
Livia
Maduri
|
General Counsel and
Corporate Secretary
|
100,000
|
|
TOTAL
|
1,
210,000
|
About Khiron Life Sciences Corp.
Khiron Life Sciences Corp. is the dominant integrated medical
cannabis company in Latin America.
Khiron has core operations in Latin
America, along with activity in North America and Europe, and is licensed in Colombia for the cultivation, production,
domestic distribution, and international export of both
tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.
The Company delivers best in class regulatory compliance, is fully
authorized to manufacture and fill prescriptions for high- and
low-THC medical cannabis in Colombia and has the first approved line of
CBD cosmetic products on shelf in Colombia, and available in
the United States and the
United Kingdom.
With a focused regional strategy and patient oriented
approach, the Company combines global scientific expertise,
agricultural advantages, branded product market entrance
experience and education to drive prescription and brand
loyalty to address priority medical conditions such as chronic
pain, epilepsy, depression and anxiety in the Latin American
market of over 620 million people. The Company is led by Co-founder
and Chief Executive Officer, Alvaro
Torres, together with an experienced executive team,
and a knowledgeable Board of Directors that includes former
President of Mexico, Vicente Fox.
Visit Khiron online at investors.khiron.ca and on Instagram
@khironlife.
Cautionary Notes
Forward-Looking Statements
This press release may contain certain "forward-looking
information" and "forward-looking statements" within the meaning of
applicable securities legislation. All information contained herein
that is not historical in nature may constitute forward-looking
information. Khiron undertakes no obligation to comment analyses,
expectations or statements made by third-parties in respect of
Khiron, its securities, or financial or operating results (as
applicable). Although Khiron believes that the expectations
reflected in forward-looking statements in this press release are
reasonable, such forward-looking statement has been based on
expectations, factors and assumptions concerning future events
which may prove to be inaccurate and are subject to numerous risks
and uncertainties, certain of which are beyond Khiron's control,
including the risk factors discussed in Khiron's Annual Information
Form which is available on Khiron's SEDAR profile
at www.sedar.com. The forward-looking information contained in
this press release is expressly qualified by this cautionary
statement and are made as of the date hereof. Khiron disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
information, whether as a result of new information, future events
or otherwise.
Neither the TSXV nor its Regulation Services Provider (as
that term is defined in the policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this press
release.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/khiron-announces-shareholder-approval-of-amended-and-restated-option-plan-and-restricted-share-unit-plan-and-grants-of-rsus-301128556.html
SOURCE Khiron Life Sciences Corp.